José Lopes, PhD, managing science editor —

First-line treatment of cold agglutinin disease (CAD) should employ a combination of Rituxan (rituximab) and bendamustine, according to a review study. The scientists also highlight the potential of therapies targeting the complement system, which are undergoing clinical trials. The research, “Cold agglutinin disease: current challenges…

A new case report described a man with altered body distribution of red blood cells (RBCs), which could have been caused by cold agglutinin disease (CAD). The study, “Abnormal Biodistribution of 99mTc Red Blood Cell Labeled Multi-Gated Acquisition Scan in the Presence of Suspected Cold Agglutinin Disease,”…

Off-label treatment with Soliris (eculizumab) was well-tolerated and lessened hemolysis — red blood cell destruction — and transfusion requirements in patients with cold agglutinin disease (CAD), a Phase 2 trial showed. The study, “Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2…